Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy
By Zaeem Shoaib
Shares of Greenwich LifeSciences rose after the company said it is preparing for filing a biologics license application for its experimental breast cancer immunotherapy GLSI-100 with the U.S. Food and Drug Administration.
The Stafford, Texas.-based biopharmaceutical company's shares were up more than 5.7% to $8.79 in recent trading. The stock is down almost 48% in the last 12 months.
Greenwich LifeSciences is currently studying GLSI-100 in phase 3 trials in the U.S. and Europe for the prevention of recurrences in certain breast cancer patients who have previously undergone surgery.
The company said about 30 clinical sites in the U.S. are currently recruiting patients and it expects to add 10 sites in 2024, bringing the total sites in the U.S. to about 35 to 40 sites.
Greenwich LifeSciences said it also has contracts in place to add up to an additional 105 to 120 sites in Europe subject to regulatory approval, which is expected in 2024.
Write to Zaeem Shoaib at zaeem.shoaib@wsj.com
(END) Dow Jones Newswires
February 14, 2024 10:15 ET (15:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth